Literature DB >> 31636801

Escherichia coli Endocarditis Presenting With Septic Shock in an Immunocompetent Female Patient.

Christos Davoulos1, Maria Lagadinou1, Athanasios Moulias2, Christos Triantos1, Nikolaos Koutsogiannis2, Markos Marangos3, Stelios F Assimakopoulos3.   

Abstract

Escherichia coli (E. coli) is a rare cause of infective endocarditis, despite being a common cause of bacteremia. E. coli endocarditis affects most frequently immunocompromised elderly women, especially those with diabetes mellitus. We present a case of a 78-year-old female immunocompetent patient, presenting with septic shock and multiple organ dysfunction syndrome. E. coli was isolated in all sets of blood cultures and in urine culture and a contrast-enhanced abdominal computed tomography (CT) scan revealed spleen and left kidney infracts. Transthoracic echocardiography revealed a large (> 15 mm) mobile mass on the atrial side of the posterior mitral valve leaflet. The patient was initially treated with intravenous ceftriaxone and ciprofloxacin for 2 weeks with successful clinical response and clearance of bacteremia, was then subjected to valve replacement (with isolation of E. coli from replaced valve cultures) and continued antibiotic therapy for additional 4 weeks postoperatively. E. coli has emerged in recent years as an important cause of bacteremia, especially in the elderly. In selected patients, as those with persistent Gram-negative bacteremia or severe sepsis/septic shock, echocardiography is of paramount importance for the diagnosis of Gram-negative endocarditis and should be included in our diagnostic algorithm of patient's evaluation. Copyright 2019, Davoulos et al.

Entities:  

Keywords:  Bacteremia; E. coli; Gram-negative endocarditis; Infective endocarditis; Septic shock

Year:  2019        PMID: 31636801      PMCID: PMC6785298          DOI: 10.14740/cr940

Source DB:  PubMed          Journal:  Cardiol Res        ISSN: 1923-2829


Introduction

Infective endocarditis (ΙΕ) is a life-threatening disease that results in cardiac dysfunction and development of metastatic infections. It remains a severe clinical condition characterized by high rates of morbidity and mortality [1]. Gram-positive bacteria cause the vast majority of IE cases; however, nowadays Gram-negative bacilli (GNB) have gained attention owing to their increasing spread and its associated high morbidity and mortality rates and health care costs [1, 2]. Contemporary published experience in Gram-negative IE is limited and the larger body of data derives from studies on IE due to the so-called “HACEK” group, that includes the genuses Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella and Kingella. Escherichia coli (E. coli) is a rare cause of IE occurring most frequently in immunocompromised elderly women, especially those with diabetes mellitus [3]. Among 2,761 patients with definite IE enrolled in the International Collaboration on Infective Endocarditis Prospective Cohort Study (ICE-PCS) database, non-HACEK Gram-negative organisms were the cause in 49 (1.8%): E. coli was the cause in 29% of them (0.51%) [4]. In another multicenter prospective study conducted from 2004 to 2011, from the Italian Endocarditis Study Group, 58 cases of non-HACEK Gram-negative endocarditis amongst 1,722 patients were reported (3.3%) and E. coli was the etiologic factor in 18 patients (1%) [2]. Urinary tract infection was the most common source of infection, whilst other risk factors for acquisition of non-HACEK GNB endocarditis included the presence of immunosuppression or cardiac implantable electronic device [2]. In the aforementioned study, the overall in-hospital mortality was 13.8% (all deaths were attributable to IE), while 1-year cumulative mortality was 30.6%, with a cumulative IE-related 1-year mortality of 22.4%. We present herein a rare case of E. coli endocarditis, developed in an immunocompetent female patient, presenting with septic shock and multiple septic emboli in kidneys and spleen.

Case Report

A 78-year-old female patient was admitted to the University Hospital of Patras, Western Greece, with septic shock and multiple organ dysfunction syndrome with depressed mental function, cardiac failure, respiratory alkalosis and disseminated intravascular coagulation (DIC). Patient’s relatives reported that the patient presented fever up to 40 °C with rigor of 3 days’ duration associated with dysuria, while had been prescribed second-generation cephalosporin for 2 days without any improvement. No other complaints were reported. Her past medical history was unrevealing. On physical examination, body temperature was 39.4 °C, heart rate was 108 beats per minute, blood pressure was 80/40 mm Hg and respiratory rate was 25 breaths per minute. There was mild peripheral cyanosis and oxygen saturation was 92% on room air. The patient presented with a Glasgow coma scale score of 11. Cardiac auscultation revealed the presence of an S3 gallop, while rales were heard over the lung bases. The abdomen was distended with diminished bowel sounds and there was a positive Giordano sign on percussion of the left flank area. An arterial blood gas revealed pH of 7.48, PaCO2 of 29 mm Hg, PaO2 of 62 mm Hg and HCO3- of 21 mmol/L. Electrocardiography (ECG) revealed sinus tachycardia without any ischemic changes. Furthermore, laboratory tests showed raised white blood cells count with polymorphonuclear predominance, anemia, thrombocytopenia, raised aspartate aminotransferase and alanine aminotransferase, indirect hyperbilirubinemia, elevated lactate dehydrogenase (LDH) and creatinine phosphokinase (CPK) levels, elevated troponin (ΤnI) and C-reactive protein (CRP) (Table 1). Prothrombin time (PT) and partial thromboplastin time (PTT) were prolonged and d-dimers were increased, while fibrinogen was reduced. Microscopic examination of peripheral blood smear revealed several schistocytes and neutrophils’ left shift. Urinalysis showed pyuria and positive nitrates. Blood and urine cultures were taken on admission. Chest X-ray showed redistribution of pulmonary vessels. A contrast-enhanced abdominal computed tomography (CT) scan revealed spleen and left kidney infracts (Fig. 1). The patient underwent transthoracic echocardiography, which revealed global left ventricular hypokinesia with left ventricular ejection fraction of 40% and a large (> 15 mm) mobile mass on the atrial side of the posterior mitral valve leaflet (Fig. 2).
Table 1

Laboratory Tests on Admission and After 2 Weeks of Antimicrobial Therapy

VariableAdmission14th dayReference value
WBC (/µL)17,7008,5004,000 - 11,000
Hemoglobin (g/dL)10.611.211.8 - 17
Platelets (/µL)67,000180,000150,000 - 400,000
PT (s)181313
PTT (s)393924 - 36
D-dimers (µg/mL)1.720.40.0 - 0.5
Fibrinogen (mg/dL)160280200 - 400
Creatinine (mg/dL)1.31.00.9 - 1.6
Urea (mg/dL)1094015 - 54
LDH (U/L)312190120 - 230
SGOT (U/L)20339< 40
SGPT (U/L)11635< 40
Bilirubin direct (mg/dL)0.70.3< 0.4
Bilirubin indirect (mg/dL)2.10.6< 0.75
CPK/CPK-ΜΒ (U/L)1,449/27110/17< 140
ΤnI (pg/mL)905.9090 - 15.6
CRP (mg/dL)21.862.4< 0.5

WBC: white blood cell; PT: prothrombin time; PPT: partial thromboplastin time; LDH: lactate dehydrogenase; SGOT: serum glutamic oxalocetic transaminase; SGPT: serum glutamic pyruvic transaminase; CPK: creatinine phosphokinase; TnI: troponin; CRP: C-reactive protein.

Figure 1

Contrast-enhanced abdominal computed tomography demonstrating infracts in left kidney (a, b, white arrows) and at the periphery of spleen (c, d, white arrows).

Figure 2

Echocardiography (parasternal long axis view): a large (> 15 mm) mobile mass on the atrial side of the posterior mitral valve leaflet is seen (arrow).

WBC: white blood cell; PT: prothrombin time; PPT: partial thromboplastin time; LDH: lactate dehydrogenase; SGOT: serum glutamic oxalocetic transaminase; SGPT: serum glutamic pyruvic transaminase; CPK: creatinine phosphokinase; TnI: troponin; CRP: C-reactive protein. Contrast-enhanced abdominal computed tomography demonstrating infracts in left kidney (a, b, white arrows) and at the periphery of spleen (c, d, white arrows). Echocardiography (parasternal long axis view): a large (> 15 mm) mobile mass on the atrial side of the posterior mitral valve leaflet is seen (arrow). In parallel the patient was supported by administration of intravenous crystalloids 30 mL/kg. Loading doses of broad-spectrum antibiotic therapy consisted of intravenous meropenem (2 g), intravenous vancomycin (15 mg/kg BW) and gentamicin (5 mg/kg BW), which were thereafter adjusted according to patient’s estimated glomerular filtration rate (GFR). Due to persistent hypotension despite the initial crystalloid fluid challenge, norepinephrine was administered to raise mean arterial pressure at 65 mm Hg. After these therapeutic interventions, hypotension was reversed, and the patient showed gradual clinical and laboratory improvement. E. coli was isolated in all sets of blood cultures and in urine culture that were taken on admission. Antimicrobial susceptibility testing was performed by the Kirby Bauer disc diffusion method [5]. The isolate was found to be resistant only to ampicillin (endogenous). Consequently, the treatment was de-escalated and the patient was treated with intravenous ceftriaxone (2 g every 24 h) and ciprofloxacin (400 mg every 12 h). The patient had a successful clinical response to treatment with resolution of symptoms and signs of infection and improvement of relevant laboratory data within 4 days, while repeated blood cultures turned out negative from the fourth day of antimicrobial therapy. A repeated echocardiography, performed a week after patient’s admission, showed improvement of left ventricular ejection fraction to 50%, while mitral valve vegetation remained stable. After completion of 2 weeks of intravenous antibiotics, the patient was in very good clinical condition with normalization of all laboratory abnormalities (Table 1) and was referred for surgical management of endocarditis. E. coli was isolated from surgical specimens of replaced valve as well, despite previous clearance of blood cultures. Post-operatively, the patient continued antibiotic therapy with ceftriaxone and ciprofloxacin for additional 4 weeks and remained free of complications for a year at follow-up.

Discussion

E. coli has emerged in recent years as an increasingly important cause of morbidity and mortality in both immunocompetent and immunosuppressed people. In an 18-year prospective survey of 3.605 bacteremia episodes, E. coli accounted for 861 (23.9%) cases and the most common site of infection was the urinary tract [6]. However, E. coli represents an uncommon etiologic factor of endocarditis accounting for a rate of about 0.5% of IE cases [4]. The low representativeness of E. coli as a cause of endocarditis, despite the high incidence of isolation of E. coli in bacteremias, is explained by its low ability to adhere to damaged or inflamed valves and to platelet-fibrin thrombus via their surface adhesins unlike Gram-positive bacteria (staphylococci, streptococci and enterococci) [7]. Previous studies have demonstrated that certain strains of E. coli are able to colonize tissue outside the gastrointestinal tract [3]. These strains, described as extra-intestinal pathogenic E. coli (ExPEC), predominantly belong to the phylogenetic group B2 and contain a variety of virulence factors that may enable the pathogens to invade and induce infections in the cardiac endothelium [8]. Administration of immunosuppressive therapy seems to constitute a risk factor for IE due to GNB, suggesting that a failure in the immune system could favor valve colonization [9]. The incidence of E. coli endocarditis increases with age and more than 70% of affected patients are females older than 70 years old [3]. Regarding advanced age, it is known that the cytotoxic responses of T-lymphocytes are decreased during senescence and therefore aging is a factor of relative immunosuppression (immunosenescence) [10]. Other risk factors for Gram-negative IE include implanted endovascular devices and invasive procedures in genitourinary and gastrointestinal systems [4, 11]. The presented case developed E. coli mitral valve endocarditis, presenting with septic shock and multiple organ dysfunction syndrome, in the absence of any underlying immunosuppression, except advanced age, or recently performed genitourinary or gastrointestinal invasive procedures. According to patient’s initial symptoms (dysuria and fever with rigors) and positive urine culture, the urinary tract was the primary infectious focus. Diagnosis of endocarditis was based on Duke criteria; the patient fulfilled one major (endocardial involvement as evidenced by oscillating intra-cardiac mass) and three minor (fever, positive blood cultures with microorganisms not typical for IE, and arterial emboli) [1]. The presence of metastatic septic infracts involving spleen and left kidney made the diagnosis of endocarditis even more compelling. The mortality rates of E. coli IE are high; patients with IE due to GNB, prospectively observed in 26 Italian centers from 2004 to 2011, presented in-hospital mortality of 13.8%, which rose to 30.6% at 1 year [2]. Gram-negative septic shock has a mortality rate of 12-38% [12-14]. The combination of the aforementioned diseases would reasonably result in a highly lethal clinical condition. The early institution of appropriate empiric antimicrobial therapy and hemodynamic resuscitation contributed majorly in the positive clinical outcome of the presented patient. Beyond antimicrobial treatment, surgical management of such patients is important to improve survival. In our case, the patient met the following criteria for surgical treatment: IE mitral valve with large vegetations (> 10 mm) in combination with embolic episodes. For that reason, she received antibiotic treatment for 2 weeks and then she was referred for valve replacement, completing her medical management with a postoperative 4-week course of antibiotics. Current guidelines for management of IE recommend that non-HACEK Gram-negative endocarditis should be managed by prolonged courses of combined antibiotic therapy and cardiac surgery [1]. The necessity of cardiac surgery was underlined in the presented patient by the fact that E. coli was isolated from surgical specimens of replaced valve as well, despite previous administration of 2 weeks of appropriate therapy and clearance of blood cultures. In conclusion, despite E. coli endocarditis is a very rare condition, its incidence seems to be increasing in aged patients. A high level of suspicion is important to ensure timely diagnosis and therapy in such cases. In selected patients, as those with persistent Gram-negative bacteremia or severe sepsis/septic shock, echocardiography is of paramount importance for the diagnosis of Gram-negative endocarditis and should be included in our diagnostic algorithm of patient’s evaluation.
  13 in total

1.  Escherichia coli native valve endocarditis.

Authors:  R Micol; O Lortholary; F Jaureguy; S Bonacorsi; E Bingen; A Lefort; N Mémain; O Bouchaud; C Larroche
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

2.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.

Authors:  Anand Kumar; Daniel Roberts; Kenneth E Wood; Bruce Light; Joseph E Parrillo; Satendra Sharma; Robert Suppes; Daniel Feinstein; Sergio Zanotti; Leo Taiberg; David Gurka; Aseem Kumar; Mary Cheang
Journal:  Crit Care Med       Date:  2006-06       Impact factor: 7.598

3.  Bacteremia due to Escherichia coli: a study of 861 episodes.

Authors:  W R Gransden; S J Eykyn; I Phillips; B Rowe
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

Review 4.  Aging of the Immune System. Mechanisms and Therapeutic Targets.

Authors:  Cornelia M Weyand; Jörg J Goronzy
Journal:  Ann Am Thorac Soc       Date:  2016-12

Review 5.  Escherichia coli endocarditis: seven new cases in adults and review of the literature.

Authors:  S Branger; J P Casalta; G Habib; F Collard; D Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

Review 6.  Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Imad M Tleyjeh; Michael J Rybak; Bruno Barsic; Peter B Lockhart; Michael H Gewitz; Matthew E Levison; Ann F Bolger; James M Steckelberg; Robert S Baltimore; Anne M Fink; Patrick O'Gara; Kathryn A Taubert
Journal:  Circulation       Date:  2015-09-15       Impact factor: 29.690

7.  Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome.

Authors:  Cheol-In Kang; Sung-Han Kim; Wan Beom Park; Ki-Deok Lee; Hong-Bin Kim; Eui-Chong Kim; Myoung-Don Oh; Kang-Won Choe
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

8.  Risk Factors and Outcomes of Endocarditis Due to Non-HACEK Gram-Negative Bacilli: Data from the Prospective Multicenter Italian Endocarditis Study Cohort.

Authors:  Marco Falcone; Giusy Tiseo; Emanuele Durante-Mangoni; Veronica Ravasio; Francesco Barbaro; Maria Paola Ursi; Maria Bruna Pasticci; Matteo Bassetti; Paolo Grossi; Mario Venditti; Marco Rizzi
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

9.  Non-HACEK gram-negative bacillus endocarditis.

Authors:  Susan Morpeth; David Murdoch; Christopher H Cabell; Adolf W Karchmer; Paul Pappas; Donald Levine; Francisco Nacinovich; Pierre Tattevin; Núria Fernández-Hidalgo; Stuart Dickerman; Emilio Bouza; Ana del Río; Tatjana Lejko-Zupanc; Auristela de Oliveira Ramos; Diana Iarussi; John Klein; Catherine Chirouze; Roger Bedimo; G Ralph Corey; Vance G Fowler
Journal:  Ann Intern Med       Date:  2007-12-18       Impact factor: 25.391

Review 10.  Mechanisms of infective endocarditis: pathogen-host interaction and risk states.

Authors:  Karl Werdan; Sebastian Dietz; Bettina Löffler; Silke Niemann; Hasan Bushnaq; Rolf-Edgar Silber; Georg Peters; Ursula Müller-Werdan
Journal:  Nat Rev Cardiol       Date:  2013-11-19       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.